Associated Papers
Pharmacogenetics of First-Line Antitubercular Drugs: An Update.
Manca A et al.
Therapeutic Drug Monitoring, 2026
Comparative evolutionary and structural bioinformatic analysis of the human N-Acetyltransferase-2 (NAT2) gene with different mammalian and avian taxa.
Khan N et al.
Bmc Genomics, 2026
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.
Thomas L et al.
Annals of Medicine, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Eadon MT et al.
Clinical Pharmacology and Therapeutics, 2025
Decoding the Impact of Genetic Polymorphisms in Xenobiotic Metabolizing Enzymes and Ovarian Cancer: A Comprehensive Review.
Sistla HC et al.
Environmental and Molecular Mutagenesis, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
Residue Variations in Human N‑Acetyltransferase 2 Enzyme Alleles: From Rapid to Slow Acetylation.
Veldman W et al.
Acs Omega, 2025
Allele-specific detection of isoniazid metabolism modulating variants of N-acetyltransferase 2 enzyme and their frequencies in the Bangladeshi population.
Khan NT et al.
Gene, 2025
Colorimetric loop-mediated isothermal amplification (cLAMP) assay for the genotyping of a thrombophilia genetic risk factor, MTHFR (C677T).
Altwayan R et al.
Analytical Methods : Advancing Methods and Applications, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort.
Schiuma M et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
The N-Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case-Control Study.
Petryszyn P et al.
Pharmacology Research & Perspectives, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid.
Taylor J et al.
Southern African Journal of Hiv Medicine, 2025
A study of N-acetyltransferase 2 gene polymorphisms in the Indian population and its relationship with serum isoniazid concentrations in a cohort of tuberculosis patients.
Munshi R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2024
Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon.
Perini JA et al.
Pharmacogenetics and Genomics, 2024
Pharmacogenetics of therapies in rheumatoid arthritis: An update.
Babiker-Mohamed MH et al.
Best Practice & Research. Clinical Rheumatology, 2024
Variants in the N-acetyltranferase 2 gene, acetylator phenotypes and their association with tuberculosis: Findings in Peruvian patients.
Sánchez R et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2024
Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection.
Cho FN et al.
Bmc Infectious Diseases, 2024
Determination of NAT2 Genotypes in a Cohort of Patients with Suspected TB in the State of Rio de Janeiro.
Dutra CA et al.
Pharmaceutics, 2024
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2024
N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury.
Alés-Palmer ML et al.
Biomedicines, 2024
Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L et al.
Pharmacology Research & Perspectives, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity.
Yoon JG et al.
Experimental & Molecular Medicine, 2024
Pharmacogenetic Analysis of an 8-Year Old Girl with Reye Syndrome Associated with Use of Naproxen.
Kim B et al.
The American Journal of Case Reports, 2024
Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity.
Njagi LN et al.
Bmc Medical Genomics, 2024
Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing.
Barthélémy D et al.
Journal of Personalized Medicine, 2023
A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia.
Farasani A
Acta Biochimica Polonica, 2023
A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
Verma R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Association of NAT2, GSTT1, and GSTM1 gene polymorphisms withprostate cancer risk in Bangladeshi population.
Nesa A et al.
Gene, 2023
The rs1801280 SNP is associated with non-small cell lung carcinoma by exhibiting a highly deleterious effect on N-acetyltransferase 2.
Lawi ZK et al.
Journal of Cancer Research and Clinical Oncology, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
Development of Novel Mass Spectrum-Based Assay for Simultaneous Detection of 36 Variants in the 14 Pharmacogenetic Genes for the Japanese Population.
Yamamoto N et al.
Biological & Pharmaceutical Bulletin, 2023
N-acetyltransferase 2 genetic polymorphisms and anti-tuberculosis-drug-induced liver injury: a correlation study.
Cheng F et al.
Frontiers in Pharmacology, 2023
Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation.
Jarrar Y et al.
Pharmacogenomics and Personalized Medicine, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
Human N-acetyltransferase 2 (NAT2) gene variability in Brazilian populations from different geographical areas.
Lopes MQP et al.
Frontiers in Pharmacology, 2023
Impact of tobacco smoking in association with H2BFWT, PRM1 and PRM2 genes variants on male infertility.
Amor H et al.
Andrologia, 2022
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2022
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
Predictive role of polymorphic variants of phase II drug metabolising enzyme in modulating toxicity in North Indian lung cancer patients undergoing chemotherapy.
Walia H et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Association of NAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy.
Walia HK et al.
Pharmacogenomics, 2022
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population.
Chorfi L et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB et al.
Memorias Do Instituto Oswaldo Cruz, 2022